CytomX Therapeutics Inc. (NASDAQ:CTMX) shares shot up 8.3% during trading on Friday . The stock traded as high as $11.50 and last traded at $11.46, with a volume of 58,086 shares traded. The stock had previously closed at $10.58.

Several brokerages have recently commented on CTMX. Zacks Investment Research raised CytomX Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, May 10th. Oppenheimer Holdings Inc. reissued a “buy” rating on shares of CytomX Therapeutics in a report on Tuesday, May 10th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $19.00.

The firm has a 50 day moving average price of $10.22 and a 200-day moving average price of $12.00. The stock’s market capitalization is $412.59 million.

CytomX Therapeutics (NASDAQ:CTMX) last posted its earnings results on Wednesday, August 3rd. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.02. Analysts expect that CytomX Therapeutics Inc. will post ($1.59) earnings per share for the current fiscal year.

In other CytomX Therapeutics news, Director Timothy M. Shannon sold 48,427 shares of the stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $10.07, for a total value of $487,659.89. Following the transaction, the director now owns 134 shares of the company’s stock, valued at $1,349.38. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Ix L.P. Canaan sold 59,621 shares of the stock in a transaction dated Friday, June 3rd. The shares were sold at an average price of $10.80, for a total value of $643,906.80. The disclosure for this sale can be found here.

CytomX Therapeutics, Inc is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.